Dubois-Stringfellow Nathalie 4

What Happened

• Nathalie Dubois-Stringfellow, SVP & Chief Development Officer at Sangamo Therapeutics (SGMO), had 52,387 RSU shares vest on January 22, 2026 and surrendered 36,676 of those shares to the company to satisfy mandatory tax withholding. The filing reports the withholding at $0.40 per share (company closing price $0.3985), a disposition valued at approximately $14,615.
• This was a tax-withholding disposition (transaction code F), not an open-market sale or discretionary trade by the insider.

Key Details

• Transaction date: January 22, 2026; filing date: January 26, 2026 (filed within the required reporting window).
• Withheld/disposed: 36,676 shares at ~$0.3985–$0.40 per share; value ≈ $14,615.
• Vesting details: 52,387 shares vested on Jan 22, 2026; after withholding, the net shares delivered from that vesting installment were 15,711 (52,387 − 36,676).
• Other holdings noted in the filing: additional RSU grants that vest through 2026 and 2028, plus 10,000 shares acquired via the 2020 Employee Stock Purchase Plan (5,000 on May 30, 2025 and 5,000 on Nov 28, 2025).
• Footnote clarification: the withheld shares were surrendered solely for mandatory tax withholding under Sangamo’s 2018 Equity Incentive Plan and are reported as a disposition to the issuer for SEC purposes.

Context

• This transaction is routine tax withholding on vested RSUs and should not be read as a discretionary sale or signal of sentiment. It reflects compensation vesting mechanics (a common insider filing type) rather than a market trade.